ProShare Advisors
CGON icon

ProShare Advisors’s CG Oncology CGON Stock Holding History

ProShare Advisors’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$892K Buy
12,553
+204
+2% +$13.3K ﹤0.01% 831
2026
Q1 		$836K Sell
12,349
-1,434
-10% -$81.2K ﹤0.01% 842
2025
Q4 		$572K Buy
13,783
+1,512
+12% +$62.6K ﹤0.01% 1062
2025
Q3 		$494K Sell
12,271
-2,033
-14% -$59.1K ﹤0.01% 1114
2025
Q2 		$372K Sell
14,304
-846
-6% -$20.4K ﹤0.01% 1294
2025
Q1 		$371K Sell
15,150
-1,411
-9% -$39.7K ﹤0.01% 1273
2024
Q4 		$475K Buy
16,561
+7,599
+85% +$260K ﹤0.01% 1301
2024
Q3 		$338K Buy
+8,962
New +$314K ﹤0.01% 1382

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ProShare Advisors's CGON Position: Q2 2026 in Review

ProShare Advisors increased its CG Oncology (CGON) stake by 1.7% in Q2 2026, buying an estimated $13.3K and bringing the position to 12,553 shares worth $892K. The position accounts for ﹤0.01% of the portfolio, ranked #831.

ProShare Advisors first reported a position in CGON in Q3 2024 and has held it in 8 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • ProShare Advisors held 12,553 shares of CG Oncology worth $892K as of Q2 2026.
  • ProShare Advisors bought 204 CG Oncology shares in Q2 2026, an estimated $13.3K.
  • CG Oncology made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #831 holding.
  • ProShare Advisors first reported a position in CG Oncology in Q3 2024 and has held it in 8 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.